Osteogenesis imperfecta associated with isolated growth hormone deficiency
Authors:
K. Kubejová; Ľ. Podracká
Authors‘ workplace:
Klinika detí a dorastu LF UPJŠ a DFN, Košice
Published in:
Čes-slov Pediat 2014; 69 (2): 114-120.
Category:
Case Report
Overview
We report a case of 9.5-year-old boy with isolated GH deficiency and osteogenesis imperfecta type IV. The basis for prevention of pathological fractures in patients with this „brittle bone disease“ is the therapy with antiresorptive drugs – bisphosphonates. Experimental therapy of osteogenesis imperfecta is based on treatment with growth hormone because of its osteoanabolic effect. Due to combination of his two major diagnoses, we start simultaneous treatment with intravenous pamidronate and rHuGH (recombinant growth hormone).
Key words:
osteogenesis imperfecta, growth hormone deficiency, bisphosphonates, recombinant growth hormone
Sources
1. Antoniazzi F, Monti E, Venturi G, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol 2010; 163: 479.
2. Bayer M. Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0–18 years. Osteoporos Int 2014; 25 : 729–736.
3. Beary J, Chines A. Osteogenesis imperfecta: Clinical features and diagnosis. www.uptodate.com; 07/2013.
4. Beary J, Chines A. Osteogenesis imperfecta: Management and prognosis. www.uptodate.com; 08/2013.
5. Bianchi LM. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 2010; 25: 37–47.
6. Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev 2010; 86: 743.
7. Castillo H, Samson-Fang L. Effects of bisphosphonates in children with osteogenesis imperfekta. Dev Med Child Neurol 2009; 51 (1): 17–29.
8. Chines A, Petersen DJ, Schranck FW, Whyte MP. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 1991; 119: 51.
9. Chines A, Boniface A, McAlister W, Whyte M. Hyper-calciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone 1995; 16: 333.
10. Cundy T. Recent advances in osteogenesis imperfecta. Calcif Tissue Int 2012; 90: 439–449.
11. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 4th ed. London: Academic Press, 2000: 1–212.
12. Kovács L. Osteogenesis imperfecta. Pediatr Prax 2012; 13 (3): 141.
13. Marini JC, Bordenick S, Heavner G, Rose S, Chrou-sos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 1993 Jan 15; 45 (2): 261–264.
14. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003; 18: 237.
15. Marini JC, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007; 28 (3): 209–221.
16. Renaud A. Radiographic features of osteogenesis imperfecta. Insights Imaging 2013; 4: 417–429.
17. Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2010; 23: 73.
18. Samson-Fang L. Growth in Osteogenesis Imperfecta. Handbook of Growth and Growth Monitoring in Health and Disease. Springer Science + Business Media, 2012: 1829–1840.
19. Šormová L, et al. Analýza mutací genu COL1A1 českých pacientu s diagnózou osteogenesis imperfecta, typ I-IV. EJBI 2012; 8 (5): 30–37.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2014 Issue 2
Most read in this issue
- Complications of surgical treatment of hydrocephalus
- The results of expanded newborn screening in the Czech Republic
- Osteogenesis imperfecta associated with isolated growth hormone deficiency
- Anthropometric, hormonal and metabolic changes in prepubertal children born as SGA (small for gestational age), with decreased growth, treated with the growth hormone, after the first year of therapy